LumiThera Receives FDA Authorization for Valeda Treatment for Dry AMD

The U.S. FDA has granted LumiThera authorization to market its Valeda Light Delivery System, the first FDA-authorized device designed to treat vision loss in patients with dry age-related macular degeneration (AMD). This significant approval, obtained through the De Novo authorization pathway, marks a major milestone in noninvasive treatments for dry AMD.